دورية أكاديمية
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
| العنوان: | Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) |
|---|---|
| المؤلفون: | Buse, JB, Rosenstock, J, Sesti, G, Schmidt, WE, Montanya, E, Brett, JH, Zychma, M, Blonde, L, Ahmed, A, Alvarsson, M, Anderson, C, Aoki, A, Aranko, S, Bailey, B, Barbonta, D, Baur, C, Bednarczyk-Kaluzny, M, Blevins, T, Bode, B, Bressler, P, Brusco, O, Byrd, L, Byrne, M, Caldarella, F, Cheatham, W, Christ, E, Christiansen, JS, Comas, LM, Cooper, J, Corder, C, Corser, B, Courreges, JP, Creteanu, G, Cuddihy, R, Derezinski, T, Downey, H, Duckor, S, Eidenmüller, M, Elliott, S, Farrell, J, Fusco, F, Gaczarek-Belczyk, E, Gallwitz, B, Garber, A, Gerber, P, Gibney, J, Glodowska, K, Gollapudi, G, Gouet, D, Greco, S, Grill, V, Gudnason, S, Guerci, B, Gumprecht, J, Henriksen, JE, Hermansen, K, Hippler, S, Hoekstra, J, Hoffman, B, Hollander, P, Jaeckel, E, Jain, R, Janez, A, Kaiser, M, Kaladas, J, Kapoor, A, Kayne, D, Keller, U, Kempe, HP, Klein, E, Klonoff, D, Koehler, L, Korytkowski, M, Laine, DH, Le Devehat, C, Lervang, HH, Levinson, L, Lewin, A, Lilavivat, U, Lipetz, R, Lubin, B, Luedemann, J, Madsbad, S, Mäkelä, J, Marck, C, Matejek, N, Menéndez, E, Milenkovic, T, Mira, R, Moberg, E, Musat, D, Nolan, J, Ollins, R, Ortiz-Carrasquillo, R, Osei, K, Peterson, G, Philippe, J, Pietri, A, Piletic, M, Polaszewska-Muszynska, M, Pollock, J, Prager, R, Radparvar, A, Ratcliff, L, Reed, J, Reeves, M, Rock, K, Sall, K, Schabowski, J, Schernthaner, G, Schwartz, S, Segiet, T, Serfer, G, Sieradzki, J, Smith, D, Søfteland, E, Solano, FV, Stasinska, T, Staut, M, Stearns, P, Stoll, M, Strand, J, Tamayo, R, Toplak, H, Townsend, R, Vaag, A, Vance, C, Wascher, T, Weinstein, R, Weiss, D, Wendisch, U, Wenzl-Bauer, V, Whittier, F, Wizemann, E |
| المصدر: | Buse, JB; Rosenstock, J; Sesti, G; Schmidt, WE; Montanya, E; Brett, JH; Zychma, M; Blonde, L; Ahmed, A; Alvarsson, M; Anderson, C; Aoki, A; Aranko, S; Bailey, B; Barbonta, D; Baur, C; Bednarczyk-Kaluzny, M; Blevins, T; Blonde, L; Bode, B; . (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet, 374(9683), pp. 39-47. London: Elsevier 10.1016/S0140-6736(09)60659-0 |
| بيانات النشر: | Elsevier |
| سنة النشر: | 2009 |
| المجموعة: | BORIS (Bern Open Repository and Information System, University of Bern) |
| الوصف: | BACKGROUND: Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight loss. We compared the efficacy and safety of liraglutide, a human GLP-1 analogue, with exenatide, an exendin-based GLP-1 receptor agonist. METHODS: Adults with inadequately controlled type 2 diabetes on maximally tolerated doses of metformin, sulphonylurea, or both, were stratified by previous oral antidiabetic therapy and randomly assigned to receive additional liraglutide 1.8 mg once a day (n=233) or exenatide 10 microg twice a day (n=231) in a 26-week open-label, parallel-group, multinational (15 countries) study. The primary outcome was change in glycosylated haemoglobin (HbA(1c)). Efficacy analyses were by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00518882. FINDINGS: Mean baseline HbA(1c) for the study population was 8.2%. Liraglutide reduced mean HbA(1c) significantly more than did exenatide (-1.12% [SE 0.08] vs -0.79% [0.08]; estimated treatment difference -0.33; 95% CI -0.47 to -0.18; p<0.0001) and more patients achieved a HbA(1c) value of less than 7% (54%vs 43%, respectively; odds ratio 2.02; 95% CI 1.31 to 3.11; p=0.0015). Liraglutide reduced mean fasting plasma glucose more than did exenatide (-1.61 mmol/L [SE 0.20] vs -0.60 mmol/L [0.20]; estimated treatment difference -1.01 mmol/L; 95% CI -1.37 to -0.65; p<0.0001) but postprandial glucose control was less effective after breakfast and dinner. Both drugs promoted similar weight losses (liraglutide -3.24 kg vs exenatide -2.87 kg). Both drugs were well tolerated, but nausea was less persistent (estimated treatment rate ratio 0.448, p<0.0001) and minor hypoglycaemia less frequent with liraglutide than with exenatide (1.93 vs 2.60 events per patient per year; rate ratio 0.55; 95% CI 0.34 to 0.88; p=0.0131; 25.5%vs 33.6% had minor hypoglycaemia). Two patients taking both exenatide and a sulphonylurea had a major hypoglycaemic episode. INTERPRETATION: ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://boris.unibe.ch/32623Test/ |
| الإتاحة: | https://doi.org/10.1016/S0140-6736Test(09)60659-0 https://boris.unibe.ch/32623Test/ |
| حقوق: | info:eu-repo/semantics/restrictedAccess |
| رقم الانضمام: | edsbas.1E0038F7 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |